Sponsored Webinar San Diego Section, AACC

Free to Members and their Guest

Assessing Cardiovascular Risk in Women Considering Menopausal Hormone Therapy

Tuesday, March 11, 2014

11:00am PDT - 12:00pm PDT

Location:
USCD Center for Advanced Laboratory Medicine
UC San Diego, 10300 Campus Point Drive, Suite 150, San Diego, CA 92121
Conference Room B (not Conference Room C as for previous meetings). Use the entrance to the left of the “UC San Diego Health System” sign on the outside of the building. Suite 150 is the first door on the right after you enter the lobby. Call 858-657-5680 or ask the receptionist to call 7-5680 for entry to Suite 150. Conference Room B is to your left after you enter Suite 150.

Speaker:

JoAnn E. Manson, MD, DrPH, Chief, Division of Preventive Medicine and Co-Director, Connors Center for Women's Health and Gender Biology, Brigham and Women's Hospital; Michael and Lee Bell Professor of Women's Health and Professor of Medicine, Harvard Medical School, Boston, MA

When the results of the Women’s Health Initiative (WHI) Estrogen Plus Progestin study demonstrated that menopausal hormone therapy (HT) did not decrease cardiovascular risk as expected and was associated with an increased risk of developing breast cancer, clinicians stopped prescribing it routinely to women undergoing menopause. However, HT is still prescribed to manage the symptoms of menopause, and recent studies have shown that many newly menopausal women have a favorable benefits:risk profile on HT. The key is to apply risk-stratification strategies and personalization of care to identify appropriate candidates for treatment and to avoid HT in women likely to have adverse events.

Attend this important webinar and know:

• What recent data are telling us about the relationship between HT and CVD risk
• Which women can benefit most from HT and which women should avoid HT
• What role labs can play in helping clinicians assess CVD risk in women considering HT
• Why a personalized approach to the prediction of risk for CVD and other events while on HT makes sense

Target Audience
This program is designed for laboratory directors, clinicians, pathologists, diagnostic manufacturers, and anyone else involved in cardiovascular disease risk assessment of menopausal women.